Global Footprint Lantheus maintains a diversified global presence with headquarters in Massachusetts and offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, enabling multi-region sales and localized support. This footprint can facilitate cross-border supply agreements, regional regulatory coordination and fast access to partners in oncology, neurology and cardiology.

Manufacturing Partnerships The company emphasizes external manufacturing through its External Manufacturing leadership, indicating openness to contract manufacturing arrangements. This creates opportunities to propose scaling production for radiopharmaceuticals, supply chain optimization and QA driven partnerships for multi-year programs.

Imaging Leadership Lantheus is at the forefront of radiodiagnostics with LNTH-2513 PET/CT achieving industry recognition and high-profile data presentations at SNMMI and ASCO. Opportunities exist to collaborate on clinical trials, commercialization of imaging agents and integration with hospital imaging workflows.

Investor Momentum Active participation in major investor conferences and market chatter about strategic options, including potential acquisition discussions, signal growth ambition and openness to strategic partnerships, licensing deals or channel partnerships.

Scale Opportunity With revenue in the 1B to 10B range, a NASDAQ listing and a sizable workforce, Lantheus represents an enterprise-scale partner capable of long-term procurement, large contract commitments and collaborative development programs across its radiopharmaceutical portfolio.